Alpha Tau Medical (DRTS) Investor presentation summary

Technology and therapeutic approach

• Alpha DaRT uses localized alpha particle radiotherapy to precisely destroy solid tumors while sparing healthy tissue, leveraging the decay chain of Radium-224 for potent, short-range cytotoxic effects.

• Demonstrates broad potential applicability for local tumor control and shows signs of immuno-stimulatory activity, with potential for use alone or in combination with other cancer therapies.

• Over 150 patents granted and more than 200 applications pending, supporting a robust intellectual property position.

Clinical development and milestones

• Multiple pivotal and pilot studies are underway or planned for recurrent cutaneous SCC, pancreatic cancer, and recurrent GBM, with key data readouts and potential FDA submissions anticipated in 2026.

• Early clinical data in skin cancer showed a 100% complete response rate in a pilot study, with most adverse events being mild or moderate.

• Pancreatic cancer trials report a 19% objective response rate and a 97% disease control rate (excluding feasibility patients), with ongoing survival analyses in key sub-populations.

• Combination trials with checkpoint inhibitors in head and neck cancers show a 75% systemic objective response rate and no serious adverse events related to Alpha DaRT.

Market opportunity and unmet need

• Targeting high unmet need indications including cutaneous SCC, head and neck SCC, prostate, liver, breast, GBM, and pancreatic cancers.

• U.S. annual incidence: 1.8 million cSCC cases, 54,000 HNSCC cases, and 66,000 pancreatic cancer cases, with the majority not eligible for surgery.

• GBM represents a particularly high unmet need, with a 93% five-year mortality rate and average survival of only 8 months.